Quick Order

Canine CD137 / 4-1BB / TNFRSF9 Protein (Fc Tag)

DatasheetReviewsRelated ProductsProtocols
Canine TNFRSF9 Protein Product Information
Synonym:CD137, 4-1BB, TNFRSF9
Protein Construction:A DNA sequence encoding the canine TNFRSF9 (XP_850336.1) (Met1-Ser185) was expressed with the Fc region of human IgG1 at the C-terminus.
Species:Canine
Expressed Host:Human Cells
Shipping:In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Canine TNFRSF9 Protein QC Testing
Purity:> (89.7+9.3) % as determined by SDS-PAGE.
Endotoxin:<1.0 EU per μg protein as determined by the LAL method.
Stability:Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N Terminal:Ile 24
Molecule Mass:The recombinant canine TNFRSF9 consists 403 amino acids and predicts a molecular mass of 43.9 kDa.
Formulation:Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
Canine TNFRSF9 Protein Usage Guide
Storage:Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution:A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Canine TNFRSF9 Protein SDS-PAGE
Canine CD137 / 4-1BB / TNFRSF9 Protein (Fc Tag) SDS-PAGE
Other TNFRSF9 Recombinant Protein Products
Description: Active  
Expression host: Human Cells  
  • Slide 1
10041-H03H-100
10041-H03H-200
100 µg 
200 µg 
Add to Cart
Expression host: Human Cells  
  • Slide 1
10041-H08H-50
10041-H08H-100
50 µg 
100 µg 
Add to Cart
Expression host: Human Cells  
  • Slide 1
  • Slide 1
50811-M02H-50
50811-M02H-100
50 µg 
100 µg 
Add to Cart
Expression host: Human Cells  
  • Slide 1
  • Slide 1
70095-D08H-100
70095-D08H-200
100 µg 
200 µg 
Add to Cart
Expression host: Human Cells  
  • Slide 1
90847-K02H-20
90847-K02H-100
20 µg 
100 µg 
Add to Cart
Expression host: Human Cells  
  • Slide 1
90847-K08H-100
90847-K08H-20
100 µg 
20 µg 
Add to Cart
4-1BB/TNFRSF9/CD137 Background

CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.

Canine 4-1BB/TNFRSF9/CD137 References
  • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
  • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
  • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
  • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
  • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
  • Product nameProduct name
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"